Cargando…

Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies

OBJECTIVE: Clear information is essential to properly determine preference in medical intervention. In neovascular age-related macular degeneration, patients need to understand the balance of risk and benefit of anti-vascular endothelial growth factor (VEGF) treatment. This balance is altered by the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clearkin, Louis, Ramasamy, Balasubramanian, Wason, James, Tiew, Stephenie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579561/ https://www.ncbi.nlm.nih.gov/pubmed/31276032 http://dx.doi.org/10.1136/bmjophth-2018-000257

Ejemplares similares

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

New Therapies of Neovascular AMD beyond Anti-VEGF Injections
por: Gahn, Greggory M., et al.
Publicado: (2018)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Restating the state? /
Publicado: (2004)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Topographical Analysis of the Choriocapillaris Reperfusion After Loading Anti-VEGF Therapy in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2022)

Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD
por: Moraru, Andreea, et al.
Publicado: (2017)

Restates the Law Relating to Malpractice
Publicado: (1898)

Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization
por: Zhang, Zhao, et al.
Publicado: (2022)

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
por: Tsilimbaris, Miltiadis K., et al.
Publicado: (2016)

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
por: Khanna, Saira, et al.
Publicado: (2019)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Anti-VEGF Treatment Strategies for Wet AMD
por: Kovach, Jaclyn L., et al.
Publicado: (2012)

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes
por: Arrigo, Alessandro, et al.
Publicado: (2021)

The Plague Problem Restated with Some Expert Errors
por: Thomson, Geo. S.
Publicado: (1900)

A restatement of the natural science evidence concerning catchment-based ‘natural’ flood management in the UK
por: Dadson, Simon J., et al.
Publicado: (2017)

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
por: Holz, F G, et al.
Publicado: (2016)

Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting
por: Lüke, Jan Niklas, et al.
Publicado: (2022)

A restatement of the natural science evidence base concerning neonicotinoid insecticides and insect pollinators
por: Godfray, H. Charles J., et al.
Publicado: (2014)

A restatement of the natural science evidence base on the effects of endocrine disrupting chemicals on wildlife
por: Godfray, H. Charles J., et al.
Publicado: (2019)

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD
por: Khan, Adnan H., et al.
Publicado: (2021)

Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis
por: Chen, Guohai, et al.
Publicado: (2015)

Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography
por: Shen, Mengxi, et al.
Publicado: (2023)

A restatement of the natural science evidence base relevant to the control of bovine tuberculosis in Great Britain(†)
por: Godfray, H. Charles J., et al.
Publicado: (2013)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Complexity in Biological Organization: Deconstruction (and Subsequent Restating) of Key Concepts
por: Bizzarri, Mariano, et al.
Publicado: (2020)

A restatement of recent advances in the natural science evidence base concerning neonicotinoid insecticides and insect pollinators
por: Godfray, H. Charles J., et al.
Publicado: (2015)

A restatement of the natural science evidence base concerning the health effects of low-level ionizing radiation
por: McLean, Angela R., et al.
Publicado: (2017)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration
por: Pfau, Maximilian, et al.
Publicado: (2021)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis
por: Yin, Xiaobei, et al.
Publicado: (2022)

Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD
por: Li, Xun, et al.
Publicado: (2022)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kdi10ef2lko4jmmdc72vd2hj0v